Stoke Therapeutics (STOK) Operating Expenses (2018 - 2026)

Stoke Therapeutics has reported Operating Expenses for 9 years, with the latest figure at $59.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 26.03% year-over-year to $59.6 million; the trailing twelve-month figure through Mar 2026 stood at -$46.3 million (down 120.52% YoY), and the FY2025 full-year result was -$13.7 million, down 109.94% from the prior year.
• Operating Expenses for Q1 2026 stood at $59.6 million, up from -$155.9 million in the prior quarter.
• The five-year high for Operating Expenses was $147.1 million in Q4 2024, with the low at -$155.9 million in Q4 2025.
• Average Operating Expenses over 5 years is $24.6 million, with a median of $30.4 million recorded in 2022.
• Peak annual rise in Operating Expenses reached 2468.82% in 2025, while the deepest fall reached 205.93% in 2025.
• Tracing STOK's Operating Expenses over 5 years: stood at $30.4 million in 2022, then advanced by 6.39% to $32.4 million in 2023, then jumped by 354.33% to $147.1 million in 2024, then sank by 205.93% to -$155.9 million in 2025, then jumped by 138.27% to $59.6 million in 2026.
• The last three Operating Expenses figures came in at $59.6 million (Q1 2026), -$155.9 million (Q4 2025), and $53.7 million (Q3 2025), per Business Quant data.

Peer Comparison